#South Korea #Seoul #J.P. Morgan #LOTTE BIOLOGICS #SoluFlex Link

LOTTE BIOLOGICS Showcases Innovations at the 2025 J.P. Morgan Healthcare Conference

LOTTE BIOLOGICS, led by CEO James Park, made waves at the prestigious 2025 J.P. Morgan Healthcare Conference held in San Francisco, an event that has become a cornerstone for the pharmaceutical and biotechnology sectors. This year's gathering, taking place from January 13 to January 16, attracted an extensive roster of biotech firms, pharmaceutical giants, and healthcare investors to discuss trends in research, investment opportunities, and potential collaborations.

In his presentation, CEO Park articulated the company's transformative journey, particularly emphasizing the conversion of the Syracuse Bio Campus in New York into a Contract Development and Manufacturing Organization (CDMO) facility. He also presented ambitious plans for the Songdo Bio Campus, notably the launch of an innovative proprietary Antibody-Drug Conjugate (ADC) platform named SoluFlex Link.

Highlighting SoluFlex Link

SoluFlex Link represents a breakthrough in ADC technology, overcoming the persistent challenges of stability associated with these therapeutics. Developed in collaboration with Kanaph Therapeutics, this platform boasts a flexible design enabling compatibility with various antibodies and drug payloads, thus facilitating extensive applications in ADC development. Park underscored that this innovative solution is aimed at enhancing both production efficiency and therapeutic effectiveness, marking a significant step forward for next-generation ADC manufacturing.

Further reinforcing its credibility, LOTTE BIOLOGICS announced that the Syracuse Bio Campus underwent a flawless quality inspection last year, with no issues reported during evaluations by the U.S. FDA and Japan's PMDA. Park affirmed, "We have maintained a high-quality production system even after acquiring the facility, showcasing our capabilities as a reliable global CDMO." He illustrated that LOTTE BIOLOGICS has developed a global quality management system, establishing high standards for biopharmaceutical manufacturing that comply with international benchmarks.

Future Aspirations with Songdo Bio Campus

Construction of Plant 1 at the Songdo Bio Campus began last March, with an ambitious investment of $1 billion earmarked for this state-of-the-art facility, projected to begin commercial production by 2027. Park noted that this plant is engineered to optimize operational efficiency through automated production processes and advanced technologies. "By leveraging the geographic advantages of both Songdo and New York, we aim to maximize our operational results and satisfaction for our clients while maintaining competitive quality standards," he articulated.

Accompanying Park at this event was Yu-Yeol Shin, who recently became Vice President and Head of Global Strategy at LOTTE BIOLOGICS. This conference marked Shin's first opportunity to engage directly with peers and competitors, providing valuable insights into industry trends and facilitating important partnership discussions with key pharmaceutical entities, emphasizing LOTTE Group’s commitment to expanding its biopharmaceutical endeavors.

Establishing End-to-End ADC Partnerships

During the J.P. Morgan Conference, Park outlined the company’s robust ADC capabilities powered by SoluFlex Link and highlighted its commitment to establishing end-to-end service partnerships within North America. This initiative allows LOTTE BIOLOGICS to address the entire development spectrum, from process development to large-scale manufacturing. The Syracuse Bio Campus is positioned to produce ADC drug substances that will be supplied to drug product partners across the East and West Coasts of the U.S.

Looking Ahead

LOTTE BIOLOGICS also provided updates regarding the ongoing initiatives at the Songdo Bio Campus, where it aims to facilitate large-scale production by 2027. With the implementation of the TiterFlex Quad Bioreactor System among other advanced technologies, the company is focused on enhancing high-titer drug output, ensuring efficiency from raw material handling through production. The overarching goal is to solidify LOTTE BIOLOGICS as a premier player in the biopharmaceutical landscape by delivering innovative and high-quality therapeutic solutions.

In conclusion, LOTTE BIOLOGICS is strategically aligning its operations to meet the rising global demand for cutting-edge biopharmaceutical solutions. Under the guidance of visionary leadership, the company is not just preparing for future challenges but is actively fostering partnerships and innovations that will shape the landscape of biopharmaceutical manufacturing.